# A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

> **NCT07719023** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Ark Biopharmaceutical Co., Ltd.** · enrollment: 263 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** AK3280
- **DRUG:** Placebo
- **DRUG:** Pirfenidone

## Key facts

- **NCT ID:** NCT07719023
- **Lead sponsor:** Shanghai Ark Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2028-09-30
- **Final completion:** 2029-03-31
- **Target enrollment:** 263 (ESTIMATED)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07719023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07719023, "A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07719023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*